Elranatamab for treating relapsed or refractory multiple myeloma after anti-CD38 antibody and lenalidomide therapy

Elranatamab is in development for relapsed or refractory multiple myeloma (RRMM) after prior anti-cluster of differentiation 38 (anti-CD38) antibody and lenalidomide therapy. MM is a type of blood cancer that is characterised by an abundance of abnormal immune cells, known as plasma cells, in the bone marrow (the spongy tissue at the centre of some bones that produces the body’s blood cells). MM affects several areas of the body, such as the spine, skull, pelvis and ribs, and symptoms may include persistent bone pain, tiredness, weakness, shortness of breath, repeated infections, unusual bleeding, and kidney problems. In RRMM, the patient has gone into complete or partial remission but then the disease has returned (relapsed) or stopped responding to treatment (refractory). Outcomes for patients with disease progression is poor, therefore there is a need to develop new treatment options for RRMM.